Clinical Trial Update: A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MG-O-1002 eye drops for reducing central macular thickness in participants over 45 with neovascular age-related macular degene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• MG-O-1002

Snippet

Sponsor: Theratocular Biotek Co. | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: UNKNOWN